Table 1. Patient variables stratified by patient and tumour characteristics, treatment and comorbidities.
| Variables | Frequency | Median | IQR | |
|---|---|---|---|---|
| Patient characteristics | ||||
| Type (n = 87) | ||||
| Primary | 97.70% (n = 85) | - | - | |
| Secondary | 2.30% (n = 2) | - | - | |
| Gender (n = 87) | ||||
| Male | 62.10% (n = 54) | - | - | |
| Female | 37.90% (n = 33) | - | - | |
| BMI (n = 61) | - | 27.73 | 23.25–31.22 | |
| Age at diagnosis (n = 87) | - | 63.00 | 51.00–73.00 | |
| Preoperative ECOG (n = 87) | ||||
| 0 | 35.60% (n = 31) | - | - | |
| 1 | 56.30% (n = 49) | - | - | |
| 2 | 6.90% (n = 6) | - | - | |
| 3 | 1.10% (n = 1) | - | - | |
| 4 | 0.00% (n = 0) | - | - | |
| Postoperative ECOG (n = 87) | ||||
| 0 | 34.50% (n = 30) | - | - | |
| 1 | 32.30% (n = 28) | - | - | |
| 2 | 18.40% (n = 16) | - | - | |
| 3 | 11.50% (n = 10) | - | - | |
| 4 | 3.40% (n = 3) | - | - | |
| Tumour characteristics | ||||
| IDH mutation (n = 79) | 6.30% (n = 5) | - | - | |
| MGMT methylation (n = 40) | 57.50% (n = 23) | - | - | |
| EGFR (n = 25) | ||||
| EGFR mutation | 64.00% (n = 16) | - | - | |
| EGFRvIII | 8.00% (n = 2) | - | - | |
| Ki67 (n = 68) | - | 20.00 | 10.00–30.00 | |
| GFAP mutation (n = 56) | 98.20% (n = 55) | - | - | |
| Treatment | ||||
| EOR (n = 87) | ||||
| Biopsy | 14.90% (n = 13) | - | - | |
| STR | 49.40% (n = 43) | - | - | |
| GTR | 35.60% (n = 31) | - | - | |
| Temozolomide (n = 87) | 77.00% (n = 67) | - | - | |
| Temozolomide average dose (n = 70) | - | 220.00 | 172.48–296.25 | |
| Radiotherapy(n = 87) | 78.20% (n = 68) | - | - | |
| Radiotherapy total dose (n = 70) | - | 60.00 | 40.05–60.00 | |
| Received another CT (n = 87) | 37.90% (n = 33) | - | - | |
| Dexamethasone (n = 87) | 75.90% (n = 66) | - | - | |
| Preoperative dexamethasone (n = 87) | 67.80% (n = 59) | |||
| Postoperative dexamethasone (n = 85) | 58.80% (n = 50) | |||
| Anti-convulsants (n = 87) | 63.20% (n = 55) | - | - | |
| Comorbidities (n = 87) | ||||
| Neurological condition | 9.20% (n = 8) | - | - | |
| Dyslipidaemia/Hypercholesterolaemia | 27.60% (n = 24) | - | - | |
| Type II diabetes | 18.40% (n = 16) | - | - | |
| Hypertension | 39.10% (n = 34) | - | - | |
| Depression | 8.00% (n = 7) | - | - | |
| Other cancer | 10.30% (n = 9) | - | - | |
| Previous surgery | 26.40% (n = 23) | - | - | |
BMI = body mass index, ECOG = Eastern Cooperative Oncology Group, IDH = isocitrate dehydrogenase, MGMT = O6methylguanine DNA methyltransferase, EGFR = epidermal growth factor receptor, GFAP = glial fibrillary acidic protein, EOR = extent of resection, STR = subtotal resection, GTR = gross total resection.